About Us Strategy & Mission Our Values Our People Our Board Our Scientific Advisors Our Collaborations Contact Our Programs Pipeline C. difficile Infection Enterobacteriaceae Clinical Trials Our Science Discuva Platform Scientific Literature & Publications Investors Investor Center Press Releases Announcements, Financial Reports & Filings Email Alerts Share Price Data Analyst Coverage Corporate Governance Shareholder Meetings Careers
Press Releases Our latest press releases are available to read in this section Press Releases Date Range Explore Search Press Releases / 11 Aug 2021 Summit Therapeutics Provides Update on Ri-CoDIFy Trials Press Releases / 11 Aug 2021 Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021 Press Releases / 12 Jul 2021 Summit Therapeutics Presents Breakthrough Research Data from Ph II Studies, including Evidence Validating Microbiome Preservation, Potential Benefit for the Control of Antimicrobial Resistance, and a Novel Mechanism of Action, for its Investigational Drug Ridinilazole Press Releases / 01 Jul 2021 Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster Press Releases / 08 Jun 2021 Summit Therapeutics set to join Russell 3000® Index Press Releases / 03 Jun 2021 Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting Press Releases / 18 May 2021 Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority Press Releases / 18 May 2021 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021 Press Releases / 18 May 2021 Summit Therapeutics Announces Closing of $75 Million Rights Offering Press Releases / 06 May 2021 Summit Therapeutics Publishes Scientific Updates to Corporate Website Press Releases / 05 May 2021 Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering Press Releases / 21 Apr 2021 Summit Therapeutics Announces Commencement of Rights Offering 1 2 … 28 29 >>
Press Releases / 11 Aug 2021 Summit Therapeutics Provides Update on Ri-CoDIFy Trials Press Releases / 11 Aug 2021 Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021 Press Releases / 12 Jul 2021 Summit Therapeutics Presents Breakthrough Research Data from Ph II Studies, including Evidence Validating Microbiome Preservation, Potential Benefit for the Control of Antimicrobial Resistance, and a Novel Mechanism of Action, for its Investigational Drug Ridinilazole Press Releases / 01 Jul 2021 Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster Press Releases / 08 Jun 2021 Summit Therapeutics set to join Russell 3000® Index Press Releases / 03 Jun 2021 Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting Press Releases / 18 May 2021 Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority Press Releases / 18 May 2021 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021 Press Releases / 18 May 2021 Summit Therapeutics Announces Closing of $75 Million Rights Offering Press Releases / 06 May 2021 Summit Therapeutics Publishes Scientific Updates to Corporate Website Press Releases / 05 May 2021 Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering Press Releases / 21 Apr 2021 Summit Therapeutics Announces Commencement of Rights Offering
Press Releases / 11 Aug 2021 Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021
Press Releases / 12 Jul 2021 Summit Therapeutics Presents Breakthrough Research Data from Ph II Studies, including Evidence Validating Microbiome Preservation, Potential Benefit for the Control of Antimicrobial Resistance, and a Novel Mechanism of Action, for its Investigational Drug Ridinilazole
Press Releases / 01 Jul 2021 Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster
Press Releases / 18 May 2021 Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
Press Releases / 18 May 2021 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
Press Releases / 05 May 2021 Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
